.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Fortis Healthcare is preparing to host a landmark two-day international conference in New Delhi. This summit focuses on the future of cancer care under the theme \"Beyond Evidence-Based Oncology.\" Consequently, the event aims to bridge the gap between clinical evidence and real-world application. Healthcare professionals will explore innovative strategies to integrate newer technologies into daily practice. Furthermore, the summit serves as a vital platform for sharing insights that improve patient outcomes across diverse oncology disciplines.
The event will feature a massive gathering of medical minds. Specifically, over 500 national and 100 international faculty members from 25 countries will participate. In addition, representatives from 50 cancer centers across India will join the dialogue. These experts will discuss critical advancements in proton therapy and MR-guided radiotherapy. Moreover, sessions will cover surgical oncology, genomics, and pediatric hematology. Therefore, the summit represents a comprehensive effort to advance global oncology standards.
Dr. Nitesh Rohatgi, Principal Director of Medical Oncology, highlights that collaboration is essential for progress. He believes that the future of cancer care relies on adapting evidence into personalized patient pathways. Thus, the summit creates an ecosystem where researchers can challenge conventional approaches. Additionally, clinicians will explore the next frontier of cancer management. This collaborative environment ensures that the latest innovations reach the patients who need them most.
Dr. Ankur Bahl also emphasized the importance of improving access to cutting-edge therapies. By bringing together the finest global minds, Fortis aims to foster meaningful dialogue. This exchange of ideas will ultimately translate into better survival rates. Furthermore, the focus remains on enhancing the quality of life for cancer patients. Consequently, this summit is a significant step toward strengthening global oncology networks.
Q1: What is the primary focus of the Fortis Cancer Summit?
The summit focuses on sharing real-world insights and newer innovations to move beyond standard evidence-based oncology into personalized patient care.
Q2: Which advanced technologies will be discussed at the event?
The summit features sessions on Proton therapy, MR-guided radiotherapy (MR Linac), genomics, and various oncology sub-disciplines.
Q3: How many countries are represented at this international summit?
The event includes international faculty from over 25 countries, alongside hundreds of national experts from across India.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Fortis Healthcare hosts a global oncology summit in New Delhi to discuss innovative strategies, proton therapy, and the future of personalized cancer care....
5 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
